SGLT2 Inhibitors Cut Osteoarthritis Risk 8% More Than GLP-1 RAs in Type 2 Diabetes Patients
Background
Patients with type 2 diabetes mellitus (T2DM) frequently experience comorbidities like osteoarthritis (OA). Both sodium-glucose co-transporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) offer metabolic and anti-inflammatory benefits, which could theoretically impact OA progression. However, the comparative effects of these two prominent drug classes on OA incidence in the T2DM population have remained unclear. This study addresses that gap by comparing their real-world impact on OA risk.
Study Design
This retrospective cohort study utilized the TriNetX database, enrolling adults with T2DM newly prescribed either SGLT2 inhibitors or GLP-1 RAs between January 2017 and December 2019. After rigorous propensity-score matching to balance baseline characteristics, 452,445 patients were included in each treatment group. The primary outcome assessed was the incidence of OA over a five-year follow-up period. Secondary outcomes included specific OA subtypes like knee OA and hip OA, as well as surgical interventions such as total knee arthroplasty (TKA) and total hip arthroplasty (THA), and major joint injections.
Results
The SGLT2 inhibitor group demonstrated a significantly lower risk of overall osteoarthritis compared to the GLP-1 RAs group, with a hazard ratio (HR) of 0.921 (95% CI, 0.895-0.946). This translates to an approximately 7.9% lower risk of OA. The protective effect was even more pronounced for knee OA, where SGLT2 inhibitor users experienced a substantial reduction in risk (HR, 0.831; 95% CI, 0.783-0.882).
Key Findings
- SGLT2 inhibitors reduced overall OA risk by 7.9% (HR 0.921) compared to GLP-1 RAs in T2DM patients.
- Knee OA risk was significantly lower with SGLT2 inhibitors (HR 0.831; 95% CI, 0.783-0.882).
- SGLT2 inhibitor users had 8.5% fewer major joint injections (HR 0.915; 95% CI, 0.882-0.951).
- No significant differences were observed in total hip or knee arthroplasty risk between groups.
Why It Matters
This large-scale cohort study suggests that SGLT2 inhibitors may offer an additional, previously underappreciated benefit for type 2 diabetes patients: a reduced risk of osteoarthritis, particularly knee OA. This finding could influence treatment selection for T2DM patients who also have or are at high risk for OA, potentially guiding clinicians to prioritize SGLT2 inhibitors in such cases. While this observational data is compelling, further prospective clinical trials are needed to confirm causality and explore the underlying mechanisms, such as direct cartilage protection or systemic anti-inflammatory effects. For individuals managing T2DM, this adds another dimension to the well-established cardiovascular and renal benefits of SGLT2 inhibitors.
sglt2-inhibitors
glp-1-receptor-agonists
type-2-diabetes
osteoarthritis
knee-oa
cohort-study